Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer

  • Stewart Sell
  • Carleton T. Garrett
Part of the Contemporary Biomedicine book series (CB, volume 12)


Cancer markers are products of cancer cells that reflect both the less differentiated state of cancer cells from normal (oncodevelopmental markers) and the molecular changes in cancer cells that take place because of activation of cell division or inhibition of the process of programmed cell death (apoptosis). The expression of these markers by cancer cells may be used to identify them as abnormal and as an indication of their malignant potential. Thus, the study of cancer markers may contribute not only to the basic understanding of the process of carcinogenesis and the biology of cancer, but also to the diagnosis and evaluation of the prognosis of patients with cancer.


Breast Cancer Hepatocyte Growth Factor Proliferate Cell Nuclear Antigen Focal Adhesion Kinase Serological Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bloom H. J. G. and W. W. Richardson (1957), Br. J. Cancer 2, 359–377.CrossRefGoogle Scholar
  2. Burke, H. B. and D. E. Hensen (1993), Cancer 72, 3131–3135PubMedCrossRefGoogle Scholar
  3. Carter, C. L., C. Allen, and D. E. Hensen (1989), Cancer 63, 181–187.PubMedCrossRefGoogle Scholar
  4. Chen D. W. and S. Sell. (1994), Tumor markers, in Tietz Textbook of Clinical Chemistry. C. A. Burtis and E. R. Ashwood, eds. 2nd ed. pp. 897–927.Google Scholar
  5. Clark, G. M. and W. L. McGuire (1991), Cancer Res. 51, 944–948.PubMedGoogle Scholar
  6. Cohen, C., T. Moghazy, D. Sgoutas, and P. D. DeRose (1994), Appl. Immunohistochem. 2, 9–14.Google Scholar
  7. Domagala, W., G. Striker, and A. Szadowska (1992), Am. J. Pathol. 141, 1003–1012.PubMedGoogle Scholar
  8. Donehower, L. A. and A. Bradley (1993), Biochim. Biophys. Acta 1155, 181–205.PubMedGoogle Scholar
  9. Duffy, M. J. (1993), Clin. Biochem. 26, 439–447.PubMedCrossRefGoogle Scholar
  10. Elston, C. W. and I. O. Ellis (1991), Histopathology 19, 403–410.PubMedCrossRefGoogle Scholar
  11. Escot C., C. Theillet, R. Lideriau, et al. (1986), Proc. Natl. Acad. Sci. USA 83, 4834–4838.PubMedCrossRefGoogle Scholar
  12. Eskelinen, M. J., P. K. Lipponen, Y. Collan, and K. J. Syrjanen (1991), Eur. J. Cancer 27, 830–834.Google Scholar
  13. Field, J. K. and D. A. Spandidos (1990), Anticancer Res. 10, 1–22.PubMedGoogle Scholar
  14. Fisher, E. R., C. Redmond, and B. Fisher (1980), Pathol. Annu. 15, 239–251.PubMedGoogle Scholar
  15. Gasparini, G., F. Pozza, and A. L. Harris (1992), J. Natl. Cancer Inst. 85, 1206–1219.CrossRefGoogle Scholar
  16. Harris, C. C. and M. Hollstein (1993), N. Eng. J. Med. 329, 1318–1327.CrossRefGoogle Scholar
  17. Humphrey, P. A., D. W. Franquemont, W. A. Geary, et al. (1994), Appl. Immunohistochem. 2, 22–28.Google Scholar
  18. Hurlimann, J. (1993), Path. Res. Pract. 189, 996–1003.PubMedCrossRefGoogle Scholar
  19. Kandalaft, P. L., K. L. Chang, C. W. Ahn, et al. (1993), Cancer 71, 2756–2763.PubMedCrossRefGoogle Scholar
  20. Kramer, B. S. et al. (1993), Ann. Int. Med. 119, 914–923.PubMedGoogle Scholar
  21. Logue, L. J. (1993), Clin. Chem. 39, 2435–2438.PubMedGoogle Scholar
  22. Lonn, U., S. Lonn, B. Nilsson, and B. Stenkvist (1994), Breast Cancer Res. Treatment 29, 237–245.CrossRefGoogle Scholar
  23. Mettlin, C. (1993), Cancer 72, 1050–1055.PubMedCrossRefGoogle Scholar
  24. Miki, Y, J. Swensen, S. Shattuck-Eidens, et al. (1994), Science 266, 66–71.PubMedCrossRefGoogle Scholar
  25. Miller, W. R., R. A. Elton, J. M. Dixon, U. Chetty, and D. M. A. Watson (1990), Br. J. Cancer 61, 263–266.PubMedCrossRefGoogle Scholar
  26. National Cancer Institute Consensus Dev. Confer. Statement on Treatment of Early Stage Breast Cancer (1990), NIH 8(6).Google Scholar
  27. Nekulova, M., M. Simickova, L. Pecen, K. Eben, I. Vermousek, P. Stratil, M. Cernoch, and B. Lang (1994), Neoplasma 41, 113–118.PubMedGoogle Scholar
  28. Ogura S., S. Abe, N. Sukoh, et al. (1992), Cancer 70, 63–68.PubMedCrossRefGoogle Scholar
  29. Owen, N. C. (1992), New cancer products in Serological Cancer Markers. S. Sell, ed. Humana, Totowa, NJ. pp. 495–523.Google Scholar
  30. Sahin, A. A. and N. Sneige (1993) Cancer Bull. 45, 495–499.Google Scholar
  31. Schwartz, G. F., R. Schwarting, P. Rabindranauth, and G. C. Finkel (1993), Clin. Chem. 39, 2404–2412.PubMedGoogle Scholar
  32. Schwartz, M. K. (1993), Clin. Chem. 39, 2397–2403.PubMedGoogle Scholar
  33. Sell, S. and R. Reisfeld (eds.) (1985), Monoclonal Antibodies in Cancer. Humana, Totowa, NJ.Google Scholar
  34. Sell, S. and B. Wahren (eds.) (1982), Human Cancer Markers, Humana, Totowa, NJ. Sell, S. (ed.) (1992), Serological Cancer Markers. Humana, Totowa, NJ.Google Scholar
  35. Sell, S. (1993), Crit. Revs. Oncogenesis 4, 419–433.Google Scholar
  36. Sell, S. (ed.) (1980), Cancer Markers: Diagnostic and Developmental Significance. Humana, Totowa, NJ.Google Scholar
  37. Sidransky D, T. Tokino, S. R. Hamilton, et al. (1992), Science 256, 102–105.PubMedCrossRefGoogle Scholar
  38. Sigurdsson, N., B. Baldetorp, A. Borg, et al. (1990), N. Eng. J. Med. 322, 1045–1053.CrossRefGoogle Scholar
  39. Stenmark-Askmalm, M. O. Stal, S. Sullivan, et al. (1994), Eur. J. Cancer 30A, 175–180.CrossRefGoogle Scholar
  40. Stoschek, C. M. and L. E. King (1986), Cancer Res. 46, 1030–1037.Google Scholar
  41. Thor, A. D., D. H. Moore, S. M. Edgerton, et al. (1992), J. Natl. Cancer Inst. 84, 845–855.PubMedCrossRefGoogle Scholar
  42. Yu, H, E. P. Diamandis, and D. J. A. Sutherland (1994), Clin. Biochem. 27, 75–79.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • Stewart Sell
  • Carleton T. Garrett

There are no affiliations available

Personalised recommendations